ReferenceID 1120
Aloperine Relieves Type 2 Diabetes Mellitus via Enhancing GLUT4 Expression and Translocation
Front Pharmacol
Aloperine (ALO), a quinolizidine alkaloid isolated from Sophora alopecuroides L. used in the traditional Uygur medicine, induced a significant increase in cellular glucose uptake of L6 cells, suggesting it has the potent
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 1120
- Evidence Id
- 17710
- Core Evidence Id
- 17710
- Source Reference Id
- 2216
- Herb2 Reference Id
- HBREF003013
- Subject Paper Key
- HBIN015319_33568989
- Pubmed Id
- 33568989
- Doi
- 10.3389/fphar.2020.561956
- Paper Title
- Aloperine Relieves Type 2 Diabetes Mellitus via Enhancing GLUT4 Expression and Translocation
- Paper Abstract
- Aloperine (ALO), a quinolizidine alkaloid isolated from Sophora alopecuroides L. used in the traditional Uygur medicine, induced a significant increase in cellular glucose uptake of L6 cells, suggesting it has the potential to relieve hyperglycemia. Therefore, we investigated the effects of ALO on type 2 diabetes mellitus (T2DM) through in vitro and in vivo studies. The translocation of glucose transporter 4 (GLUT4) and changes in intracellular Ca2+ levels were real-time monitored in L6 cells using a laser scanning confocal microscope and related protein kinase inhibitors were used to explore the mechanism of action of ALO. Furthermore, high fat diet combined with low-dose streptozotocin (STZ) was used to induce T2DM in rats, and ALO was given to the stomach of T2DM rats for 4 weeks. In vitro results showed that ALO-induced enhancement of GLUT4 expression and translocation were mediated by G protein-PLC-PKC and PI3K/Akt pathways and ALO-enhanced intracellular Ca2+ was involved in activating PKC via G protein-PLC-IP3R-Ca2+ pathway, resulting in promoted GLUT4 plasma membrane fusion and subsequent glucose uptake. ALO treatment effectively ameliorated hyperglycemia, glucose intolerance, insulin resistance and dyslipidemia, alleviated hepatic steatosis, protected pancreatic islet function and activated GLUT4 expression in insulin target tissues of T2DM rats. These findings demonstrated that ALO deserves attention as a potential hypoglycemic agent.
- Journal
- Front Pharmacol
- Publish Year
- 2021
- Experiment Subject
- rat; l6 cells
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Dyslipidemia; Glucose Intolerance; Hepatic Steatosis; Type 2 Diabetes Mellitus; Hyperglycemia
- Paper Title Cn
- Paper Title En
- Aloperine Relieves Type 2 Diabetes Mellitus via Enhancing GLUT4 Expression and Translocation
- Bilingual Status
- semi_complete